America Is Surrendering Its Biotech Lead to China – Inside Sources

From the early days of the Manhattan Project to the race to develop artificial intelligence, America has long recognized that being at the forefront of emerging technologies is critical to our national defense. While the global AI race is perhaps the most important story in the world now, outcompeting China in that arena is not enough to secure American dominance in the 21st century. The United States must compete across multiple fronts.

Today, global scientific competition is increasingly shifting to biotechnology, and there are warning signs that America is losing its edge. Recent efforts to abandon or restrict messenger RNA (mRNA) technology are the starkest examples of how, in many cases, the United States is undermining its own advantage. We cannot afford to undercut American innovation while our competitors are racing ahead.

Military medicine experts have described mRNA vaccines as the equivalent of ballistic missile defense against biological threats. The speed and flexibility of the mRNA platform enable us to design, manufacture and distribute vaccines targeting emerging pathogens in a fraction of the time compared to prior technologies.

Supporting innovation in this field is important not only to combat the next pandemic but also to defend against man-made pathogens. The rapid development of AI is raising the stakes of this threat, potentially handing adversaries or terrorist groups new tools to engineer bioweapons and deploy them against American civilians or troops.

Yet, despite the clear advantages mRNA and other next-generation treatments can deliver, Washington is losing ground. In December 2025, the National Security Commission on Emerging Biotechnology submitted a report to the Senate detailing how China has surpassed the United States in key areas of biopharmaceutical innovation. The commission called it “a new inflection point in this great power competition.”

The latest data tell a story that should alarm every U.S. policymaker.

Nearly half, 46 percent, of all mRNA vaccines in global clinical development originate in China. That is 18 of 39 active programs worldwide. And for cancer specifically, where mRNA shows immense potential to deliver better treatments, the gap is even more stark: as of January 2025, China had 14 active phase 1 and phase 2 mRNA cancer vaccine trials. The United States had five.

This did not happen by accident. China’s biotechnology research and development investment has surged more than 300 percent as a share of GDP over the past two decades — rising from 0.9 percent to 2.7 percent — bringing it near parity with American spending. Beijing has rightly identified biotechnology as an essential frontier of 21st-century power, and it has invested accordingly.

Federal health officials have signaled that they understand what is at stake in this race, including Health and Human Services Secretary Robert F. Kennedy Jr. He has spoken at length about making America “the hub of biotechnology innovation” and eliminating the regulatory impediments that slow life-saving treatments to market.

However, Kennedy has presided over several policies that could slow momentum in certain areas of mRNA development, including the cancellation of $500 million in contracts supporting the development of mRNA treatments to protect against future pandemics, even as broader mRNA research efforts continue.

Meanwhile, lawmakers in several states have pushed legislation to restrict or even ban mRNA treatments and research. Every clinical trial that cannot launch in Dallas or Des Moines because of regulatory uncertainty or anti-innovation policy is a gift to our competitors.

The foundation for American leadership is still here. We invented the first mRNA treatments, and we have the best scientific talent in the world.

Our country did not cede the nuclear race to the Soviet Union, and we cannot cede the biotechnology race to China now.

Beijing is betting we will argue ourselves out of winning. Let’s prove them wrong.